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Abstract
Background: Risk-stratified treatment recommendations facilitate treatment decision-making that balances patient-
specific risks and preferences. It is unclear if and how such recommendations are developed in clinical practice
guidelines (CPGs). Our aim was to assess if and how CPGs develop risk-stratified treatment recommendations for
the prevention or treatment of common chronic diseases.
Methods: We searched the United States National Guideline Clearinghouse for US, Canadian and National Institute
for Health and Clinical Excellence (United Kingdom) CPGs for heart disease, stroke, cancer, chronic obstructive
pulmonary disease and diabetes that make risk-stratified treatment recommendations. We included only those
CPGs that made risk-stratified treatment recommendations based on risk assessment tools. Two reviewers
independently identified CPGs and extracted information on recommended risk assessment tools; type of evidence
about treatment benefits and harms; methods for linking risk estimates to treatment evidence and for developing
treatment thresholds; and consideration of patient preferences.
Results: We identified 20 CPGs that made risk-stratified treatment recommendations out of 133 CPGs that made
any type of treatment recommendations for the chronic diseases considered in this study. Of the included 20
CPGs, 16 (80%) used evidence about treatment benefits from randomized controlled trials, meta-analyses or other
guidelines, and the source of evidence was unclear in the remaining four (20%) CPGs. Nine CPGs (45%) used
evidence on harms from randomized controlled trials or observational studies, while 11 CPGs (55%) did not clearly
refer to harms. Nine CPGs (45%) explained how risk prediction and evidence about treatments effects were linked
(for example, applying estimates of relative risk reductions to absolute risks), but only one CPG (5%) assessed
benefit and harm quantitatively and three CPGs (15%) explicitly reported consideration of patient preferences.
Conclusions: Only a small proportion of CPGs for chronic diseases make risk-stratified treatment recommendations
with a focus on heart disease and stroke prevention, diabetes and breast cancer. For most CPGs it is unclear how
risk-stratified treatment recommendations were developed. As a consequence, it is uncertain if CPGs support
patients and physicians in finding an acceptable benefit- harm balance that reflects both profile-specific outcome
risks and preferences.
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Background
An important goal of evidence-based health care is to
maximize benefits and minimize harms from medical
treatments. To achieve an optimal balance, patients’
individual profiles and preferences need to be consid-
ered [1]. For example, inhaled corticosteroids are used
to prevent exacerbations in patients with chronic
obstructive pulmonary disease (COPD) [2-4], but these
drugs are associated with an increased risk for pneumo-
nia and fractures [5,6]. In patients at high risk for
exacerbations, the potential benefits (preventing exacer-
bations) are likely to be larger than harms, while
patients at low risk for exacerbations may experience
more harms from inhaled corticosteroids than benefits.
Risk-stratified treatment recommendations are poten-
tially useful to support personalized medicine. Persona-
lized medicine aims at optimizing the benefit-harm
balance by considering patient profiles (combination of
characteristics) and preferences [7]. For the prevention
and treatment of chronic disease, most health care deci-
sions are sensitive to patient profiles and preferences
[8]. Risk-stratified treatment recommendations suggest
different treatment regimens for patients who are at dif-
ferent risks for outcomes [9]. For example, in the Third
Report of the National Cholesterol Education Program’s
Adult Treatment Panel treatment algorithm [10], the
recommendation for primary prevention of coronary
heart disease is based on the Framingham Risk Score.
According to different risk categories predicted by the
Framingham Risk Score, individuals with higher pre-
dicted absolute risk (10-year risk > 20%) are recom-
mended for more intensive treatments (such as
combined pharmacological and non-pharmacological
treatments) than those with lower predicted risk (10-
year risk < 10%). There is evidence that using risk-strati-
fied treatments is superior to treatments that are not
informed by a risk assessment tool [11-13].
Risk-stratified treatment recommendations only serve
their purpose of supporting personalized medicine if
valid methods were used to develop them. Because it is
not known what proportion of clinical practice guide-
lines (CPGs) make risk-stratified treatment recommen-
dations and what methods were used to develop them,
our aim was to assess the methods CPGs applied in
developing risk-stratified treatment recommendations
for the prevention or treatment of selected common
chronic diseases.
Methods
Framework for developing risk-stratified treatment
recommendations
We started by forming a framework for developing risk-
stratified treatment recommendations. Figure 1 outlines
the major steps for developing risk-stratified treatment
recommendations, each of which requires high quality
evidence from observational studies (development and
Risk assessment tool to 
estimate outcome risk
Evidence about treatment 
effects on benefit and harm 
outcomes
Application of treatment 
evidence to outcome risks
Patient preferences
Benefit harm assessment 
to define treatment 
thresholds according to 
outcome risks 
Figure 1 Important elements for the development of risk-stratified treatment recommendations.
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validation of risk assessment tools), randomized trials
(evidence about treatment effects) and studies to elicit
patient preferences (using various study designs, for
example, discrete choice experiments). It is well known
for all guidelines that evidence about treatment effects
on benefit and harm outcomes must be available. In
addition, a risk assessment tool should be available that
allows the assigning of patients to different risk cate-
gories. A method is required to estimate how treatment
evidence applies to patients at different risks and how
the benefits compare to the harms in patients at differ-
ent risks. As a result of such a benefit-harm assessment,
treatment thresholds can be defined for patients with
different risk profiles that maximize the chance for ben-
efits while minimizing harms. In addition, patient pre-
ferences for outcomes would ideally be explicitly
considered for the development of risk-stratified treat-
ment recommendations or their application in practice.
Environmental scan of clinical practice guidelines
We performed an environmental scan of CPGs, which
included a limited literature search (described below)
but not a comprehensive, systematic review of all CPGs.
We focused on CPGs for major chronic diseases and
from the United States (US), Canada, or the United
Kingdom (UK) National Institute for Health and Clinical
Excellence (NICE). The completed PRISMA checklist is
available as Additional file 1.
Data sources and searches
We searched the US National Guideline Clearinghouse
(NGC) database on February 5 2011 for CPGs with
treatment recommendations for five major chronic dis-
eases. The top five chronic diseases in the US are heart
disease, cancer, stroke, COPD and diabetes, accounting
for more than two-thirds of all deaths [14]. In the NGC
database, guidelines were categorized by disease topics
that were linked to a specific term derived from the US
National Library of Medicine’s Medical Subject Head-
ings classification.
For heart disease and stroke, we performed our search
within the Cardiovascular Diseases section of the database
(n = 442) and considered CPGs specific for primary pre-
vention of heart disease and stroke, that is, the prevention
of an event in persons free of established cardiovascular
diseases. For cancer, we chose to examine three types of
cancer with the highest mortality rates in the US (lung
cancer, prostate cancer and breast cancer) [15]. We
searched for CPGs within the Lung Neoplasms (n = 53),
Prostatic Neoplasms (n = 26) and Breast Neoplasms (n =
52) sections, respectively. For COPD, we considered CPGs
specific for COPD within the Respiratory Tract Diseases
section (n = 102). For diabetes mellitus, we considered
CPGs for type II diabetes within the Diabetes Mellitus,
Type 2 section (n = 44).
Eligibility criteria for guidelines
We included CPGs that recommended using risk assess-
ment tools to inform treatment decisions. Risk assess-
ment tools are tools to calculate the probability of
developing an event or a disease based on a prediction
model (binary outcome), or tools that make projections
about the course of disease measured by patient-
reported or other continuous outcomes (for example,
decline of functional status over time). We excluded
CPGs if they were not from the US, Canada or NICE
(UK); focused on childhood diseases; made recommen-
dations on screening, genetic counseling or diagnostic
work-up alone; or did not use any risk assessment tools
to inform risk-stratified treatment decisions. This latter
excluded category involved guidelines that recom-
mended treatments according to diagnostic criteria, as
for example based on pathological staging, rather than
according to prognostic information (for example, the
risk stratification scheme proposed by D’Amico et al. in
prostate cancer guidelines [16]).
Guideline selection
Two reviewers (TY and DV) independently reviewed the
Guideline Summary section of each CPG on the NGC
website to assess its potential eligibility. We excluded
the CPGs labeled ineligible by both reviewers. For the
other CPGs, we retrieved and examined the full text and
resolved any discrepancies in eligibility through discus-
sion or arbitration by a third reviewer (MP).
Data extraction and synthesis
We developed a standardized form to extract data from
the included CPGs and the background documents
detailing the methods used in developing CPGs when
available. We extracted general items such as guideline
title, bibliographic source, date released and guideline
developer. We then extracted information related to five
key components for developing risk-stratified treatment
recommendations (Figure 1). We extracted the following
information on risk assessment tools: the name of the
prediction model, the outcome and the timeframe (for
example, 10 years) used in the model, and whether vali-
dation of the model (for example, assessment of discri-
mination and/or calibration) was discussed in the CPGs.
We extracted information on the type of evidence used
to determine the effects of treatments on benefit and
harm outcomes (observational studies, single or several
randomized controlled trials (RCTs), or meta-analyses).
We recorded the methods to link risk prediction and
evidence on treatment effects (for example, applying
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relative risk reductions to different absolute risks calcu-
lated from the risk assessment tool). We recorded the
way the treatment benefits and harms were assessed and
how treatment thresholds (based on risk assessment
tools) were determined. We also extracted information
on assumptions made for linking risk prediction and
treatment evidence (for example, assumption of constant
relative risk reductions across the risk spectrum) and on
assumptions made for the assessment of benefits and
harms (for example, assumption that benefit and harm
outcomes can be put on a single scale and the overall net
benefit expressed as a single number indicating benefit or
harm). Finally, we noted whether patient preferences (for
example, relative importance of different benefit and
harm outcomes) were considered for developing risk-
stratified treatment recommendations. Because some
CPGs were very brief, without detailing the development
process but referring to other documents, we considered
those documents for data extraction to avoid underesti-
mating the rigor of the development process of a CPG.
Two reviewers (TY and DV) independently extracted all
relevant information from each CPG and the discrepan-
cies were resolved by discussion or third-party (MP) arbi-
tration. We constructed a table for comparison of
recommendations from each of the included CPGs.
Results
Most CPGs that we excluded (Figure 2) were on topics not
related to our study question or because they were not
from the US, Canada or NICE (UK). We excluded
60 CPGs based on NGC website review and 49 CPGs
based on the full text because they did not recommend
using a risk assessment tool. We excluded four additional
CPGs because they recommended using a risk assessment
tool but did not make any link to treatments (Figure 2).
Thus out of 133 CPGs that made treatment recommenda-
tions for the chronic diseases of interest (60 + 49 + 4 + 20
= 133 CPGs), 20 made risk-stratified treatment recom-
mendations (15%) for heart disease, stroke, type II diabetes
or breast cancer (Figure 2) [10,17-36]. The characteristics
of the 20 included CPGs are summarized in Table 1.
Risk assessment tools used to estimate baseline risk for
outcome of interest
A large proportion of CPGs (16 out of 20, 80%) were on
type II diabetes or on primary prevention of heart disease
and stroke [10,18-32], and the remaining four CPGs were
on breast cancer management [33-36]. All 16 CPGs on dia-
betes or cardiovascular disease recommended one or sev-
eral risk assessment tools to assess 10-year cardiovascular
disease risk. The Framingham Risk Score was explicitly
suggested in 12 CPGs [10,19-29]; the UK Prospective Dia-
betes Study Risk Engine was suggested in four CPGs
[21,24,30,31] for patients with diabetes, and the Prospective
Cardiovascular Münster and the Systematic Coronary Risk
Evaluation risk tools were used in one CPG [29]. Of the 16
CPGs on diabetes or cardiovascular disease, two (13%) did
not clearly specify the prediction model used for calculat-
ing 10-year cardiovascular disease risk [18,32]. Among the
four CPGs on breast cancer [33-36], two recommended
using the National Cancer Institute breast cancer risk
assessment tool to calculate 5-year risk of invasive breast
cancer [33,35]; one recommended using the Nottingham
Prognostic Index to calculate 10-year survival [36]; one
mentioned different risk assessment tools but did not
clearly define risk categories [34]. Information on the vali-
dation of the risk models was reported in seven (35%) of
the 20 included CPGs (Table 2) [10,19,20,22,29,30,35].
Treatments recommended and evidence of treatment
benefits and harms
Of the 16 CPGs for type II diabetes and primary preven-
tion of heart disease and stroke, nine (56%) suggested
specific target lipid levels for each risk category when
making recommendations about lifestyle management or
pharmacotherapy (for example, aspirin, statins and anti-
hypertensive drugs) [10,19-21,26-29,31]. The four CPGs
on breast cancer [33-36] provided recommendations on
surgery or pharmacotherapy (for example, tamoxifen,
raloxifene and aromatase inhibitors) according to risk
levels.
Sixteen (80%) of the 20 CPGs reported using evidence
on treatment benefits from RCTs or meta-analyses or
other guidelines [10,18-25,27,29-32,35,36]. One CPG
(5%) did not report quantitative information on treat-
ment benefits [28] and three (15%) did not clearly spe-
cify the type of studies considered [26,33,34]. Treatment
harms were only reported in 13 of the 20 CPGs (65%)
[10,18,22,23,25-27,29,30,32,33,35,36]. The source of evi-
dence on harms was specified in nine out of these 13
CPGs (69%) and included observational studies, RCTs
and meta-analyses [10,18,32,23,25,27,30,35,36]. Hetero-
geneity of treatment effects were assessed in eight (40%)
of the included 20 CPGs (Table 2) [10,18,22,23,25,
26,32,35].
Linking treatment effects to baseline risks
In reviewing how CPGs made the link between risk pre-
diction and treatment effects, we found fewer than half of
the CPGs (eight out of 20, 40%) explicitly or implicitly sta-
ted that they applied evidence of relative risk reductions
from RCTs and/or meta-analyses to different absolute
risks [10,18,23-27,32]. For instance, the U.S. Preventive
Services Task Force (USPSTF) guideline [25] applied a
32% risk reduction of myocardial infarction (in men) and a
17% risk reduction of strokes (in women) with regular
aspirin use to absolute outcome risks and assumed that
the effects were constant across risk levels and age
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categories. One (5%) of the 20 included CPGs [33], instead
of applying treatment evidence to all risk levels, used the
evidence from RCTs with the same risk profile (high
breast cancer risk) population for which the recommenda-
tion was made. Eleven (55%) of the included CPGs did not
report the way in which they linked risk prediction to
treatment effects (Table 2) [19-22,28-31,34-36].
Benefit-harm assessment to define treatment thresholds
and consideration of patient preferences
Only a small proportion (two out of 20, 10% [25,35]) of
CPGs explicitly stated that they planned to perform bene-
fit and harm assessment as the basis for making risk-strati-
fied treatment recommendations. To define treatment
thresholds, only the USPSTF guideline quantitatively
719 citations identified in the NGC database
442 Cardiovascular Diseases
53 Lung Neoplasms
26 Prostatic Neoplasms
52 Breast Neoplasms
102 COPD within Respiratory Tract Diseases
44 Diabetes Mellitus, Type 2
636 Excluded
472 Unrelated topic1
14 Not focused on adult
46 Not from US, Canada, or UK NICE 
44 Not focused on treatments
60 Not using risk assessment tools
20 Included (guidelines using risk assessment tools to 
inform risk-stratified treatment decisions)
12 Cardiovascular disease and related conditions
1 Cardiovascular disease and type 2 diabetes
3 Type 2 diabetes
4 Breast cancer
719 NGC website review
83 Full text review
66 Excluded
9 Unrelated topic1
1 Not focused on treatments
49 Not using risk assessment tools
4 No link between risk tools and treatments
1 Electronic copies not available
2 Duplicates2
3 Included (guidelines being referenced by others 
in the recommendations)
Figure 2 Guideline search and review process. 1For cardiovascular diseases, we excluded guidelines not focused on primary prevention. 2Two
citations in Diabetes Mellitus, Type 2 were the same guidelines as in Cardiovascular Diseases. NGC: US National Guideline Clearinghouse; NICE: UK
National Institute for Health and Clinical Excellence.
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weighed treatment benefits and harms by putting the
expected benefit and harm outcomes on the same scale
(events per 1,000 persons treated over 10 years). The
USPSTF guideline recommended using aspirin when the
treatment benefits (number of myocardial infarctions or
strokes prevented per 1,000 persons treated over 10 years)
outweigh the treatment harms (number of gastrointestinal
bleedings or hemorrhagic strokes per 1,000 persons
Table 1 Characteristics of the included guidelines.
Guideline
identifier, year
released
Guideline developer and
country
Disease or condition Guideline title
Cardiovascular disease and related condition
NCEP, 2002
(updated 2004)
[10,14]
National Heart, Lung, and Blood
Institute, US
Hypercholesterolemia
and coronary heart
disease
National Cholesterol Education Program Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III)
NICE1, 2006 [15] National Institute for Health and
Clinical Excellence, UK
Cardiovascular disease Statins for the Prevention of Cardiovascular Events
AHA1, 2006 [16] American Heart Association and
American Stroke Association, US
Ischemic stroke Primary Prevention of Ischemic Stroke: A Guideline From the
American Heart Association/American Stroke Association Stroke
Council
AHA2, 2007 [17] American Heart Association, US Cardiovascular disease Evidence-Based Guidelines for Cardiovascular Disease Prevention in
Women: 2007 Update
MSC1, 2008 [18] Medical Services Commission,
British Columbia, Canada
Cardiovascular disease Cardiovascular Disease - Primary Prevention
NICE2, 2008 [19] National Collaborating Centre for
Primary Care, UK
Cardiovascular disease Lipid Modification. Cardiovascular Risk Assessment and the
Modification of Blood Lipids for the Primary and Secondary
Prevention of Cardiovascular Disease
ACCP, 2008 [20] American College of Chest
Physicians, US
Coronary artery disease The Primary and Secondary Prevention of Coronary Artery Disease:
American College of Chest Physicians Evidence-Based Clinical
Practice Guidelines (8th Edition)
MSC2, 2008 [21] Medical Services Commission,
British Columbia, Canada
Hypertension Hypertension - Detection, Diagnosis and Management
USPSTF, 2009
[22]
U.S. Preventive Services Task Force,
US
Cardiovascular disease Aspirin for the Prevention of Cardiovascular Disease: U.S.
Preventive Services Task Force Recommendation Statement
UMHS1, 2009
[23]
University of Michigan Health
System, US
Coronary heart disease
and stroke
Screening and Management of Lipids
ICSI, 2009 [24] Institute for Clinical Systems
Improvement, US
dyslipidemia and
coronary heart disease
Lipid Management in Adults
MQIC, 2009 [25] Michigan Quality Improvement
Consortium, US
Hypercholesterolemia Screening and Management of Hypercholesterolemia
Cardiovascular disease and type 2 diabetes
ES, 2008 [26] The Endocrine Society, US Cardiovascular disease
and Type 2 diabetes
Primary Prevention of Cardiovascular Disease and Type 2 Diabetes
in Patients at Metabolic Risk: An Endocrine Society Clinical Practice
Guideline
Type 2 diabetes
NICE3, 2008 [27] National Clinical Guideline Centre
for Acute and Chronic Conditions,
UK
Type 2 diabetes Type 2 Diabetes: National Clinical Guideline for Management in
Primary and Secondary Care (update)
MSC3, 2010 [28] Medical Services Commission,
British Columbia, Canada
Type 2 diabetes Diabetes Care
ADA, 2011 [29] American Diabetes Association, US Type 2 diabetes Standards of Medical Care in Diabetes - 2011
Breast cancer
UMHS2, 2007
[30]
University of Michigan Health
System, US
Breast cancer Common Breast Problems
NSGC, 2007 [31] National Society of Genetic
Counselors, US
Breast cancer and
ovarian cancer
Risk Assessment and Genetic Counseling for Hereditary Breast and
Ovarian Cancer: Recommendations of the National Society of
Genetic Counselors
ASCO, 2009 [32] American Society of Clinical
Oncology, US
Breast cancer American Society of Clinical Oncology Clinical Practice Guideline
Update on the Use of Pharmacologic Interventions Including
Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer
Risk Reduction
NICE4, 2009 [33] National Collaborating Centre for
Cancer, UK
Breast cancer Early and Locally Advanced Breast Cancer. Diagnosis and
Treatment
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Table 2 Risk-stratified treatment recommendations of the included guidelines.
Guideline title NCEP NICE1 AHA1 AHA2
Risk assessment tools
Risk prediction
model
Framingham Risk Score 10-year risk of developing CVD,
not referring to a specific risk
model
Framingham Risk Score Framingham Risk Score
Outcome of
interest and its
timeframe
CHD (10 years) CVD (CHD and stroke, 10
years)
CHD (10 years) CHD (10 years)
Information on
validation of the
model provided in
the guideline
Yes Unclear Yes Yes
Evidence of treatment effects
Treatment
considered
LDL-lowering therapy,
therapeutic lifestyle change
and LDL goals
Statin Diet, weight management,
physical activity, drug
therapy and LDL-C goals
Lifestyle management,
pharmacotherapy and LDL-C
target levels
Target population Adults Adults at risk of CVD Adult patients at increased
risk of stroke
Adult women 20 years and
older
Type of studies
considered in the
evidence of
treatment benefits
Single or several RCTs
Meta-analyses
Single or several RCTs
Meta-analyses
Single or several RCTs
Meta-analyses
Single or several RCTs
Meta-analyses
Type of studies
considered in the
evidence of
treatment harms
Observational studies
Single or several RCTs
Single or several RCTs
Meta-analyses
Treatment harms not
reported
Treatment harms not reported
Heterogeneity of
treatment effects
assessed in the
guideline
Yes Yes No No
Application of treatment evidence to baseline risks
Methods to apply
treatment
evidence to
baseline risks
Used evidence of relative risk
reduction from RCT/meta-
analysis and applied it to
different absolute risks
Unclear, presumably used
evidence of relative risk
reduction from RCT/meta-
analysis and applied it to
different absolute risks
Not reported Not reported
Assumptions
specified when
applying
treatment
evidence
’For every 30-mg/dL change in
LDL-C, the relative risk for CHD
is changed in proportion by
about 30%, and the relative risk
is set at 1.0 for LDL-C = 40
mg/dL.’
’For every 1% reduction in
LDL-C levels, relative risk for
major CHD events is reduced
by approximately 1%.’
’Statins do not differ in their
relative effectiveness in a
number of subgroups: in
women compared with men
at a similar level of
cardiovascular risk; in people
with diabetes compared with
people without diabetes; or in
people aged over 65 years
compared with people aged
under 65 years.’
Not reported Not reported
Development of treatment thresholds
Risk stratification
in which different
treatments were
recommended
•10-year CHD risk > 20%
•10-year CHD risk 10 to 20%
•10-year CHD risk < 10%
•10-year CVD risk ≥20% •0 to 1 CHD risk factor
•≥2 CHD risk factors and
10-year CHD risk < 20%
•≥2 CHD risk factors and
10-year CHD risk 10% to
20%
•CHD or CHD risk
equivalent (10-year risk >
20%)
•10-year CHD absolute risk >
20%
•10-year CHD absolute risk 10%
to 20%
•10-year CHD absolute risk <
10%
Methods to
develop treatment
thresholds
Unclear Expert consensus Referring to NCEP ATP-III
guideline
Not reported
Explicitly planned
benefit and harm
assessment as the
basis for making
recommendations
No No No No
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Table 2 Risk-stratified treatment recommendations of the included guidelines. (Continued)
Patient
preferences
considered when
developing
recommendations
No No No No
Guideline title MSC1 NICE2 ACCP MSC2
Risk assessment tools
Risk prediction
model
Framingham Risk Score (for
patients without diabetes) and
UKPDS Risk Engine (for patients
with diabetes)
Framingham Risk Score Framingham Risk Score Framingham Risk Score or
UKPDS Risk Engine for patients
with diabetes
Outcome of
interest and its
timeframe
CHD (10 years) CVD (CHD and stroke, 10
years)
CHD (10 years) CHD (10 years)
Information on
validation of the
model provided in
the guideline
No Yes No No
Evidence of treatment effects
Treatment
considered
Lifestyle management,
pharmacologic treatment and
desirable lipid results
Lifestyle advice and statin Aspirin and vitamin K
antagonists
Lifestyle management and
antihypertensive drugs
Target population Men aged > 40 years and
women aged > 50 years
Adults aged 18 and older and
who have established CVD or
who are at high risk of
developing CVD
Patients at risk for
coronary artery disease
Non-pregnant adults (age 19
years and older) with
hypertension
Type of studies
considered in the
evidence of
treatment benefits
Other guidelines Meta-analyses Meta-analyses Meta-analyses
Type of studies
considered in the
evidence of
treatment harms
Treatment harms not reported Meta-analyses Single or several RCTs
Meta-analyses
Treatment harms not reported
Heterogeneity of
treatment effects
assessed in the
guideline
No Yes Yes No
Application of treatment evidence to baseline risks
Methods to apply
treatment
evidence to
baseline risks
Not reported Not reported Unclear, presumably used
evidence of relative risk
reduction from RCT/meta-
analysis and applied it to
different absolute risks
Used evidence of relative risk
reduction from RCT/meta-
analysis and applied it to
different absolute risks
Assumptions
specified when
applying
treatment
evidence
Not reported Not reported Not reported ’This assumes 20% risk
reduction of CHD based on
average outcomes for
appropriately used blood
pressure lowering medications
and statin medications.’
Development of treatment thresholds
Risk stratification
in which different
treatments were
recommended
•Framingham CHD risk ≥20%
without CHD
•Framingham CHD risk 10% to
19%
•Framingham CHD risk < 10%
•CVD risk < 20%
•CVD risk ≥20%
Moderate risk for a
coronary event (10-year
risk of a cardiac event >
10%)
Diagnosis of hypertension
confirmed and CHD risk ≥20%
over 10 years
Method to
develop treatment
thresholds
Referring to 2005 British
Columbia guideline Diabetes
Care
Referring to the NICE
technology appraisal Statins for
the Prevention of Cardiovascular
Events
Unclear, presumably
putting benefits and
harms on the same scale
and find a balance
between them
Unclear
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Table 2 Risk-stratified treatment recommendations of the included guidelines. (Continued)
Explicitly planned
benefit and harm
assessment as the
basis for making
recommendations
No Unclear No Unclear
Patient
preferences
considered when
developing
recommendations
No No No No
Guideline title USPSTF UMHS1 ISCI MQIC
Risk assessment tools
Risk prediction
model
Framingham Risk Score Framingham Risk Score Framingham Risk Score Framingham Risk Score
Outcome of
interest and its
timeframe
CHD (10 years) in men and
stroke (10 years) in women
Hard CHD (myocardial
infarction and coronary death,
10 years)
CHD (10 years) CHD (10 years)
Information on
validation of the
model provided in
the guideline
No No No No
Evidence of treatment effects
Treatment
considered
Aspirin Lifestyle changes, drug therapy
and LDL-C goals
Drug therapy and LDL
goals
Drug therapy and goal for
LDL-C
Target population Men aged 45 to 79 years and
women aged 55 to 79 years
Adults 20 to 75 years of age
without familial or severe
dyslipidemias
Adults 20 years and older
and who are dyslipidemic
Adults ≥18 years
Type of studies
considered in the
evidence of
treatment benefits
Meta-analyses Treatment benefits reported
but study type unclear
Single or several RCTs
Meta-analyses
Treatment benefits not
reported
Type of studies
considered in the
evidence of
treatment harms
Observational studies Treatment harms reported but
study type unclear
Single or several RCTs
Meta-analyses
Treatment harms not reported
Heterogeneity of
treatment effects
assessed in the
guideline
Yes Yes No No
Application of treatment evidence to baseline risks
Methods to apply
treatment
evidence to
baseline risks
Used evidence of relative risk
reduction from RCT/meta-
analysis and applied it to
different absolute risks
Used evidence of relative risk
reduction from RCT/meta-
analysis and applied it to
different absolute risks
Used evidence of relative
risk reduction from RCT/
meta-analysis and applied
it to different absolute
risks
Not reported
Assumptions
specified when
applying
treatment
evidence
There is ‘a 32% risk reduction
of MIs with regular aspirin use’
(in men) and ‘a 17% risk
reduction of strokes with
regular aspirin use’ (in women).
’The risk for gastrointestinal
bleeding increases with age.’
Not reported Not reported Not reported
Development of treatment thresholds
Risk stratification
in which different
treatments were
recommended
•Men aged 45 to 59 years and
10-year CHD risk ≥4%; men
aged 60 to 69 years and 10-
year CHD risk ≥9%; men aged
70 to 79 years and 10-year
CHD risk ≥12%
•Women aged 55 to 59 years
and 10-year stroke risk ≥3%;
women aged 60 to 69 years
and 10-year stroke risk ≥8%;
women aged 70 to 79 years
and 10-year stroke risk ≥11%
•0 to 1 risk factors
•2+ risk factors and 10-year
CHD risk < 10%
•2+ risk factors and 10-year
CHD risk 10% to 20%
•0 to 1 risk factor and 10-
year CHD risk < 10%
•2+ risk factors and 10-year
CHD risk < 10%
•2+ risk factors and 10-year
CHD risk 10% to 20%
•CHD or CHD equivalent
and/or 10-year risk > 20%
•CHD or CHD risk equivalents
10-year risk > 20%
•2+ risk factors 10-year CHD
risk ≤20%
•0 to 1 risk factor
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Table 2 Risk-stratified treatment recommendations of the included guidelines. (Continued)
Method to
develop treatment
thresholds
Putting benefits and harms on
the same scale (events saved/
in excess per 1,000 people)
and find a balance between
them
Expert consensus and referring
to NCEP ATP-III guideline
Referring to NCEP ATP-III
guideline
Referring to ICSI Lipid
Management in Adults
guideline
Explicitly planned
benefit and harm
assessment as the
basis for making
recommendations
Yes No No No
Patient
preferences
considered for the
development of
recommendations
Yes No No No
Guideline title ES NICE3 MSC3 ADA
Risk assessment tools
Risk prediction
model
Framingham Risk Score,
PROCAM and SCORE
UKPDS Risk Engine UKPDS Risk Engine Not specified, presumably
Framingham Risk Score
Outcome of
interest and its
timeframe
10-year CHD risk (Framingham
and PROCAM) and 10-year
total cardiovascular mortality
(SCORE)
CHD (10 years) in patients with
diabetes
CHD (10 years) in patients
with diabetes
CVD (CHD and stroke, 10
years)
Information on
validation of the
model provided in
the guideline
Yes Yes No No
Evidence of treatment effects
Treatment
considered
Aspirin, LDL-C goals and non-
HDL-C goals
Simvastatin and statin Statin and lipid targets Aspirin
Target population Patients at high metabolic risk
for CVD
People with type 2 diabetes Non-pregnant adults with
type 2 diabetes
Patients with type 1 or type 2
diabetes mellitus
Type of studies
considered in the
evidence of
treatment benefits
Single or several RCTs
Meta-analyses
Single or several RCTs
Meta-analyses
Single or several RCTs Meta-analyses
Type of studies
considered in the
evidence of
treatment harms
Treatment harms reported but
study type unclear
Single or several RCTs Treatment harms not
reported
Treatment harms reported but
study type unclear
Heterogeneity of
treatment effects
assessed in the
guideline
No No No Yes
Application of treatment evidence to baseline risks
Methods to apply
treatment
evidence to
baseline risks
Not reported Not reported Not reported Unclear, presumably used
evidence of relative risk
reduction from RCT/meta-
analysis and applied it to
different absolute risks
Assumptions
specified when
applying
treatment
evidence
Not reported Not reported Not reported Not reported
Development of treatment thresholds
Risk stratification
in which different
treatments were
recommended
•Individuals over age 40 and
10-year risk for CHD > 10%
•10-year risk for CHD > 20%
•10-year risk for CHD 10% to
20%
•At least two major risk factors
and 10-year risk for CHD <
10%
The cardiovascular risk exceeds
20% over 10 years
•Moderate risk (< 20% 10-
year CHD risk)
•High risk (≥20% 10-year
CHD risk)
•Adults with type 1 or type 2
diabetes at increased
cardiovascular risk (10-year
CVD risk > 10%)
•Adults with diabetes and 10-
year CVD risk < 5%
•Adults with 10-year CVD risk
5% to 10%
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Table 2 Risk-stratified treatment recommendations of the included guidelines. (Continued)
Methods to
develop treatment
thresholds
Unclear, presumably putting
benefits and harms on the
same scale and find a balance
between them to recommend
using aspirin; referring to NCEP
ATP-III guideline on LDL-C and
non-HDL-C goals
Not reported Not reported Unclear, presumably putting
benefits and harms on the
same scale and find a balance
between them
Explicitly planned
benefit and harm
assessment as the
basis for making
recommendations
No No No No
Patient
preferences
considered when
developing
recommendations
No Yes No No
Guideline title UMHS2 NSGC ASCO NICE4
Risk assessment tools
Risk prediction
model
NCI Breast Cancer Risk
Assessment Tool
The guideline mentioned
different models
NCI Breast Cancer Risk
Assessment Tool
Nottingham Prognostic Index
Outcome of
interest and its
timeframe
Invasive breast cancer (5 years) Absolute risk of developing
breast cancer or the likelihood
of carrying a BRCA1 or BRCA2
mutation (unclear timeframe)
Invasive breast cancer
during the next 5-year
period and up to age 90
(lifetime risk)
Survival (10 years)
Information on
validation of the
model provided in
the guideline
No No Yes No
Evidence of treatment effects
Treatment
considered
Tamoxifen and raloxifene Tamoxifen; oral contraceptives;
prophylactic mastectomy,
prophylactic bilateral salpingo-
oophorectomy
Tamoxifen and raloxifene Aromatase inhibitors
Target population Adults age 18 and older (non-
pregnant)
Individuals at risk for hereditary
breast and ovarian cancer
Women at increased risk
of breast cancer
Women with breast cancer
Type of studies
considered in the
evidence of
treatment benefits
Treatment benefits reported
but study type unclear
Treatment benefits reported
but study type unclear
Single or several RCTs
Meta-analyses
Single or several RCTs
Type of studies
considered in the
evidence of
treatment harms
Treatment harms reported but
study type unclear
Treatment harms not reported Single or several RCTs
Meta-analyses
Single or several RCTs
Heterogeneity of
treatment effects
assessed in the
guideline
No No Yes No
Application of treatment evidence to baseline risks
Methods to apply
treatment
evidence to
baseline risks
Used evidence of relative risk
reduction from the same risk
profile population for which
the recommendation was
made
Not reported Unclear Unclear
Assumptions when
applying
treatment
evidence
Not reported Not reported Not reported Not reported
Development of treatment thresholds
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treated over 10 years). For example, the expected number
of myocardial infarctions prevented by aspirin was esti-
mated to be 16 per 1,000 men of age 60 to 69 years if men
had a 10-year risk for myocardial infarction of 5%, while
the expected number of excess gastrointestinal bleedings
was 24 and hemorrhagic strokes was one. Because the
number of excess events exceeded the number of pre-
vented myocardial infarctions, the USPSTF recommended
against the use of aspirin in men at 5% risk for myocardial
infarction and an age of 60 to 69 years. Based on observa-
tional studies, the USPSTF assumed different risks for gas-
trointestinal bleeding with aspirin according to age.
Finally, the USPSTF presented their benefit-harm assess-
ment and the resulting treatment thresholds as a matrix
table with categories for age and risk for myocardial
infarction defining each cell.
Three (15%) of the 20 CPGs qualitatively weighed the
treatment benefits and harms [23,29,32]. Nine (45%) of
the 20 CPGs made the recommendation on thresholds
based on expert consensus or referred to other guide-
lines [18,19,21,22,26-28,33,33]. Seven (35%) of the 20
CPGs did not report how they determined the treatment
thresholds when making recommendations [10,20,24,
30,31,34,36]. With regard to involving patient prefer-
ences when developing treatment recommendations,
only three (15%) of the 20 CPGs explicitly reported that
they considered patient preferences in the process
(Table 2) [25,30,36]. For example, the USPSTF focused
on major benefit (myocardial infarction) and harm
events (gastrointestinal bleeding and hemorrhagic
stroke) and assumed equal preferences (that is, impor-
tance) for those outcomes.
Discussion
We found a rather small proportion of CPGs for heart
disease, cancer, stroke, COPD and diabetes that made
risk-stratified treatment recommendations using risk
assessment tools. Most of these CPGs recommend risk
assessment tools that had been shown to accurately pre-
dict outcome risk in the target population of the CPGs
and most of the treatment evidence is based on RCTs
and meta-analyses. For the majority of the CPGs, how-
ever, it was not explicitly explained how treatment
effects on benefit and harm outcomes were estimated
for patients at different risks. Perhaps most importantly,
it was unclear for all but one CPG how treatment
thresholds were determined to generate risk-stratified
treatment recommendations.
We formed a framework for the development of risk-
stratified treatment recommendations (Figure 1) to sys-
tematically identify the strengths and weaknesses of cur-
rent CPGs. Our findings suggest that risk assessment tools
were carefully appraised and selected during the develop-
ment of CPGs. For example, some CPG developers
Table 2 Risk-stratified treatment recommendations of the included guidelines. (Continued)
Risk stratification
in which different
treatments were
recommended
Women at high risk (5-year risk
of invasive cancer ≥1.7%)
The guideline made risk-
stratified recommendations,
but it is unclear how they
defined high risk, moderate
risk and low risk
Premenopausal and
postmenopausal women
with a 5-year projected
breast cancer risk ≥1.66%
or with lobular carcinoma
in situ
•Postmenopausal women with
estrogen-receptor-positive
early invasive breast cancer not
at low risk (those in the
Excellent Prognosis Group or
Good Prognosis Group in the
Nottingham Prognostic Index)
•Postmenopausal women with
estrogen-receptor-positive
early invasive breast cancer not
at low risk and who have been
treated with tamoxifen for 2 to
3 years
Method to
develop treatment
thresholds
Expert consensus Not reported Expert consensus Unclear
Explicitly planned
benefit and harm
assessment as the
basis for making
recommendations
No No Yes No
Patient
preferences
considered when
developing
recommendations
No No No Yes
CHD: coronary heart disease; CVD: cardiovascular disease; LDL: low-density lipoprotein; LDL-C: low-density lipoprotein cholesterol; MI: myocardial infarction; NCEP
ATP-III: National Cholesterol Education Program Adult Treatment Panel III; NCI: National Cancer Institute; NICE: National Institute for Health and Clinical Excellence;
HDL-C: high-density lipoprotein cholesterol; PROCAM: Prospective Cardiovascular Münster; RCT: randomized clinical trial; SCORE: Systematic Coronary Risk
Evaluation; UKPDS: United Kingdom Prospective Diabetes Study.
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critically appraised validation studies of risk tools to judge
their calibration (agreement between predicted and
observed risk) and discrimination (probability that those
with an event receive higher risk predictions that those
without an event) [10,30]. Minimizing misclassification of
outcome risks is important to avoid over- or under-treat-
ment [37-39]. While some CPGs recommended specific
risk assessment tools, one CPG suggested using the risk
assessment tool that is most likely to be accurate in the
specific population of interest [30]. However, the set of
CPGs selected in this study may give an overoptimistic
picture of risk assessment tools proposed by guidelines.
For many diseases and geographical locations other than
the US, Canada and the UK, calibrated and discriminative
risk assessment tools may not exist. A strength of existing
CPGs is that the majority of them relied on RCTs and
meta-analyses of RCTs for intervention effectiveness. The
CPG developers recognized limitations within this body of
evidence, including insufficient evidence on treatment het-
erogeneity (that is, subgroup effects) and scarcity of data
on harm outcomes.
We discovered a number of major limitations in how
CPGs develop risk-stratified treatment recommenda-
tions. It should be noted that some limitations propa-
gated from single, prominent CPG (for example,
National Cholesterol Education Program) to other CPGs
that adopted the approach or even the recommenda-
tions. For example, it was often unclear how the benefit
and harm outcomes were estimated for different risk
profiles. Some CPGs applied estimates on relative risk
reduction to absolute risks. This approach relies on the
assumption of constant (relative) effects across the risk
spectrum. This assumption of constant relative treat-
ment effects may be justifiable in many instances but it
is usually difficult to verify. No alternative approaches
for linking the absolute risk with treatment evidence
were used. Additional sensitivity analyses may some-
times be appropriate to explore the assumption of rela-
tive treatment effects. For example, one could obtain
risk-specific treatment estimates from large trials using
individual patient data [12]. Or, one could employ simu-
lation studies to estimate the probability of outcomes in
the population of interest by combining observational
data and treatment effects from randomized trials. It is
currently unclear what the most appropriate approach is
to link risk predictions with evidence from randomized
trials. Nevertheless, we believe CPGs should be explicit
about the method they use and acknowledge the asso-
ciated advantages and limitations (for example, assump-
tion of constant relative risk reduction).
In our view, the greatest limitation of current CPGs is
that it is unclear how treatment thresholds were devel-
oped for most of them. Some CPGs stated that the
thresholds were determined by experts. The USPSTF
guideline on aspirin [25] was the only guideline that
conducted a formal quantitative assessment by compar-
ing the expected number of benefit and harm events for
patients at different risk for myocardial infarction and
major gastrointestinal bleeding. We believe that trans-
parency will be enhanced by conducting quantitative
benefit-harm assessments alongside more qualitative
approaches, such as using expert consensus about treat-
ment thresholds.
Treatment thresholds are important because medical
decision-making is discrete (to treat the patient or not).
It is challenging to determine thresholds because clear
cuts on the (commonly) continuous benefit-harm scale
may not exist. In addition, there may often be substan-
tial uncertainty about harms and heterogeneity of treat-
ment effects as a consequence of poor reporting or a
lack of evidence from primary studies. However, this
should, in our view, not prevent CPG developers from
making risk-stratified recommendations because health
care providers need evidence-based guidance neverthe-
less and because variability in delivering health care may
be unacceptably high in the absence of guidance. Quan-
strum and Hayward [40] recently suggested an approach
that acknowledges uncertainty about treatment decision
thresholds and proposed two thresholds instead of one:
one above which physicians should recommend treat-
ments (benefits outweighing harms irrespective of
patient preferences and uncertainties about evidence
base) and one below which physicians should recom-
mend against treatments (harms outweighing benefits).
The interval between the two thresholds represents an
area where treatment could provide small benefits or
harms depending on patient preferences but also where
uncertainty about the evidence precludes CPG develo-
pers from making recommendations. Alternatively, CPG
developers could frame strong recommendations for or
against treatment for patients at outcomes risks above
or below the two thresholds, respectively, and weak
recommendations for patients at outcome risks between
the two thresholds [41].
One may criticize the approach used by the USPSTF,
assigning equal weight to benefit and harm outcomes to
calculate events expected per 1,000 people treated over 10
years, because empirical evidence suggests that patients,
on average, assign different importance to myocardial
infarction, major gastrointestinal bleeding and major
stroke, the major drivers of the benefit-harm balance of
aspirin [42]. Nevertheless, such transparency about the
relative importance of outcomes comes with several
important advantages. Users of CPGs can understand and
replicate how the treatment thresholds were derived and,
if they do not agree with certain assumptions (for example,
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equal importance of myocardial infarction and major gas-
trointestinal bleeding), they can adjust the result to derive
thresholds that would suit their settings (for example,
myocardial infarction considered twice as important as
major gastrointestinal bleeding). This would also allow the
guideline to be interpreted for an individual patient, who
may weigh the various outcomes differently than those
preferences assumed in the CPG.
The framework for developing risk-stratified treatment
recommendation we proposed may be useful for those
developing CPGs and to stimulate further research. While
much research has been done on how to select and
appraise evidence on treatment benefits and harms [43,44]
and how to judge the validity of prediction models
[37-39], it is less clear how to link risk prediction and
treatment evidence, how to select a method for benefit-
harm assessment to develop treatment thresholds, and
how to include patient preferences. It would be useful to
have empirical evidence on how the results of different
approaches for linking risk prediction and treatment evi-
dence and for defining treatment thresholds differ and
how sensitive they are to assumptions [45]. As for patient
preferences, little research has been done to find ways to
include stakeholders in the process of selecting important
outcomes, or a benefit-harm assessment method that pro-
vides the information patients need in order to make deci-
sions [46-48]. The newly founded Patient-Centered
Outcomes Research Institute is likely to contribute sub-
stantially to the questions raised.
Our study has some weaknesses. We selected guide-
lines from five major disease categories and from one
database and focused on CPGs from the US, Canada
and NICE (UK). Thus our results may not be generaliz-
able, but provide an optimistic assessment of CPGs
because we included some of the most prominent guide-
lines in medicine. For the fields of cardiovascular medi-
cine and diabetes, guideline developers have a long
tradition of making risk-stratified treatment recommen-
dations. We relied on published reports, which may not
reflect the true underlying development process for
CPGs. We considered all background documents that
were openly accessible but we may have missed some
information on the development of risk-stratified treat-
ment recommendations.
Conclusions
We found that the methods for linking risk prediction
with treatment evidence are often not reported and that it
was unclear for all but one CPG how treatment thresholds
were developed. Therefore, current CPGs for major
chronic diseases may not support patients and physicians
in finding an acceptable benefit-harm balance that reflects
profile-specific outcome risks and preferences.
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